VIVA Biotech Holdings
HKEX:1873
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
CN |
V
|
VIVA Biotech Holdings
HKEX:1873
|
1.7B HKD | 4.5 | |
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
230.2B USD | 42.2 | ||
US |
Danaher Corp
NYSE:DHR
|
196.5B USD | 52.9 | ||
US |
Agilent Technologies Inc
NYSE:A
|
45.2B USD | 39.3 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
42.1B USD | 23.6 | ||
CH |
Lonza Group AG
SIX:LONN
|
38.2B CHF | 138.9 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
56.1T KRW | -456.1 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
32.4B USD | 37.6 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
26B USD | 156 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
26B USD | 67.6 | ||
US |
Waters Corp
NYSE:WAT
|
21.1B USD | 19.4 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.